ACE-031 protocol · PepGuide

No validated protocol

Phase	How often	Dose	Units	Notes

Trials used up to 2.5 mg/kg SubQ every 2 weeks (i.e. tens of mg/dose), doses far above typical “research peptide” amounts, and that program was stopped early for bleeding. There is no validated, safe community microdose. Included for completeness; not a recommended protocol.

What to expect

Increased muscle mass in principle, but with a real bleeding-risk profile that ended its clinical development. Risk/benefit is unfavorable for physique use.

Men & women

A myostatin trap, unisex mechanism, no human sex data. High caution both sexes (its trial stopped for bleeding). Avoid in pregnancy.

Recommended mixes

Vial	Water	Strength
1 mg	1 mL	1 mg/mL

1 mg: 1 unit = 0.01 mg (10 mcg). No validated low-dose human protocol exists.

Storage

PowderFreeze-dried: -4°F.
MixedReconstituted: 36–46°F, short-dated.

Don't use if: Any bleeding disorder or anticoagulant/antiplatelet therapy · Known vascular malformations / telangiectasia · Pregnancy and lactation · Active malignancy

Stop if you notice

Any abnormal bleeding (nose, gums, skin)
New telangiectasias
Any sign of internal bleeding

Side effects

Nosebleeds, gum bleeding, skin telangiectasias (dilated vessels), headache. Vascular bleeding is the signature risk.

Drug interactions

Anticoagulants / antiplatelets / NSAIDs: compounded bleeding risk, avoid. Other growth-promoting agents: unknown combined risk.

Labs

CBC and bleeding assessment if used at all. Watch for epistaxis, gum bleeding, new skin vascular lesions.

What these labs mean →

Warnings

Mechanism-based vascular bleeding (BMP9 inhibition), ended the clinical program. No safe, validated human dosing for physique use. Activin/myostatin pathway inhibition has broad off-target effects. Not an approved drug.

Patient education

This compound’s clinical trial was stopped early for bleeding, that is the headline. There is no established safe physique dose; included for completeness, not endorsement. Do not combine with anything affecting bleeding. Stop immediately for any abnormal bleeding.

These apply on top of the universal safety rules.

Avoid with

Bleeding disorders

Anticoagulant/antiplatelet use

Vascular abnormalities

Pregnancy

Honestly: avoid pending a safe human protocol

What it does

ACE-031 is a soluble ActRIIB receptor fused to IgG1-Fc. It binds and neutralizes myostatin (GDF-8) and related ligands, releasing the brake on muscle growth and increasing muscle mass. Because the same receptor binds BMP9 (a vascular-remodeling ligand), inhibition caused bleeding events (nosebleeds, gum bleeding, skin telangiectasias); the Phase 2 Duchenne trial was terminated early on safety grounds.

Caution

Caution: the dose-limiting toxicity was vascular bleeding (epistaxis, gingival bleeding, telangiectasia) via BMP9 inhibition. This is a mechanism-based risk, not an impurity issue.

Myostatin inhibition for physique use is not supported by a safe, established human protocol.

Supply math

Not applicable, no validated safe human dose. Research compound only.

Pairs well with

Not recommended for stacking given the bleeding-risk profile.

References

PubMed clinicaltrials.gov researchdosing

From the guide, page 12.